MD, Ph.D – Senior Executive in Clinical Development & Medical Affairs.
Karin Rosén is a Biotech/pharmaceutical Senior Executive with a 20+ history of working in Senior Leadership positions SVP/VP in Global Clinical Development and US & Global Medical Affairs. Experience with Developing and Launching numerous New Biotechnology/Pharmaceutical products including Regulatory Health Authority interactions (FDA, EMA, Health Canada etc). Clinical Development Lead for phase II-IV programs. MD, Ph.D with experience in Oncology, Immunology, Asthma, Allergy, Pulmonary Fibrosis, Infectious Disease, CF, Dermatology, Food Allergy, Cardiology.
Executive Vice President & Chief Scientific Officer at Horizon Therapeutics, USA. – Focusing on rare and inflammatory diseases.
Senior Vice President, U.S. medical affairs at GlaxoSmithKline, USA. - Leading a team of >300 physicians and medical professionals in disease areas including immunology, oncology, respiratory and inflammation.
Senior Vice President, U.S. and global medical affairs at Aimmune Therapeutics, Inc., (Acquired by Nestle). Developing the first treatment for Peanut allergy.
Genentech (Part of the Roche Group), USA: Therapeutic Area Head, Immunology as well as serving as lead medical director responsible for developing Phase 2-4 clinical programs and product launches for multiple biologics in the areas of immunology, respiratory, allergy and dermatology.
Karin also holds a Medical degree (M.D.) and doctorate degree (Ph.D) from Lund University in Lund, Sweden.
On Bridging the Gap 2022, Karin will talk about what it takes to win in the US market.
Theme: Expanding to the U.S.